Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6556 to 6570 of 8909 results

  1. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued Reference number: GID-TAG375

    Technology appraisal guidance
    Discontinued

  2. Heart failure (acute decompensated) - nesiritide [ID384]

    Discontinued Reference number: GID-TAG376

    Technology appraisal guidance
    Discontinued

  3. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

    Technology appraisal guidance
    Discontinued

  4. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued Reference number: GID-TAG378

    Technology appraisal guidance
    Discontinued

  5. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  6. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

    Technology appraisal guidance
    Discontinued

  7. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  8. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

    Technology appraisal guidance
    Discontinued

  9. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued Reference number: GID-TAG385

    Technology appraisal guidance
    Discontinued

  10. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  11. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development Reference number: GID-TAG388 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued Reference number: GID-TAG389

    Technology appraisal guidance
    Discontinued

  13. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued

  14. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued Reference number: GID-TA10543

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

    Discontinued Reference number: GID-TA10546

    Technology appraisal guidance
    Discontinued